Selective silencing or inhibition of AXL resensitized CML cells to imatinib [49] and prostate cancer cells to docetaxel with reduced ATP-binding cassette B1 (ABCB1) levels [98]. The gene discussed is AXL; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.